A new report from calls for big changes in how US pharmaceuticals are priced, promoted, and sold so that treatments are more affordable and equally available to all Americans, as market mechanisms that would usually moderate prices have been blunted or eliminated.
A new report from the National Academy of Sciences, Engineering, and Medicine calls for big changes in how US pharmaceuticals are priced, promoted, and sold so that treatments are more affordable and equally available to all Americans, as market mechanisms that would usually moderate prices have been blunted or eliminated.
The report, “Making Medicines Affordable: A National Imperative,” recommends that steps be taken to address market failures that are “currently permeating” the biopharmaceutical sector: a lack of competition due to distortions in the application of patent protections; the imbalance between the negotiating power of suppliers and purchasers; and the convoluted structure of the supply chain. The report seeks methods to improve the affordability of prescription drugs without discouraging the development of new and more effective drugs for the future.
Among the report’s recommendations are the following:
The report was written by a panel of physicians, attorneys, economists, and former corporate leaders and insurance and pharmaceutical company executives who worked together to produce the independent, objective analysis. Two members of the panel filed dissenting views, as did pharma industry group Pharmaceutical Research and Manufacturers of America (PhRMA), which called the report a rehash of outdated ideas that would severely restrict patient access to innovative treatment.
The report acknowledges the biopharmaceutical sector’s success over the past several decades in developing and delivering effective drugs for improving health, combatting disease, and helping to make many health conditions previously thought to be untreatable now manageable or cured. But it decried the high and increasing costs of prescription drugs, coupled with broader trends in overall healthcare expenditures as unsustainable to society as a whole. “There is a critical need for policy changes that will ensure the availability and affordability of medicines for patients who need them,” the report notes. “There is little value in new drugs that patients cannot afford—and there is no value in drugs that do not exist. Thus, there is a fundamental tension between ensuring the availability of new drugs in the future and ensuring the affordability of those drugs that exist today.”
The report details the factors that increase the cost of drugs for patients, including:
The report also said that patients’ share of drug costs should be calculated as a fraction of the net purchase price of drugs, after rebates and discounts, rather than from list prices, to help reduce the financial burden on patients who need costly pharmaceuticals. In addition, the Justice Department and FTC should discourage direct-to-consumer advertising of prescription drugs, said the report, and discourage direct financial incentives for patients. The agencies should make sure that tax credits and incentives for development of drugs for rare diseases not be extended to widely sold drugs, and should further restrict drug company sales representatives from visiting physicians and providing free samples and other inducements.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.